GlaxoSmithKline announced that the FDA has approved Boostrix (tetanus and reduced diphtheria toxoid, acellular pertussis vaccine, adsorbed [Tdap]) for use in adults ≥65 years for active booster immunization against tetanus, diphtheria and pertussis. Boostrix is already indicated for use in patients ≥10 years of age.

For more information call (888) 825-5249 or visit www.gsk.com.